PRLD - Prelude Therapeutics Incorporated

-

$undefined

N/A

(N/A)

Prelude Therapeutics Incorporated NASDAQ:PRLD Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

Location: | Website: preludetx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-68.62M

Cash

153.6M

Avg Qtr Burn

-26.43M

Short % of Float

24.61%

Insider Ownership

9.36%

Institutional Own.

84.96%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Initiation

PRT3789 [SMARCA2 degrader] Details
Non-small cell lung carcinoma, Cancer

Phase 1

Data readout

PRT543 (PRMT5 inhibitor) Details
Myelofibrosis, Solid tumor/s, Myelodysplastic syndrome, Cancer

Phase 1

Data readout

PRT3645 (CDK4/6 inhibitor) Details
Head and neck cancer, Glioblastoma, Non-small cell lung carcinoma, Breast cancer

Phase 1

Data readout

PRT2527 (CDK9 inhibitor) Details
Acute myeloid leukemia, Solid tumor/s, Hematologic malignancies

Phase 1

Update

PRT7732 [SMARCA2 degrader] Details
Cancer, Non-small cell lung carcinoma

Phase 1

Initiation

PRT1419 (MCL1 inhibitor) Details
Hematologic malignancies, B-cell malignancies, Relapsed/refractory acute myeloid leukemia, Solid tumor/s

Failed

Discontinued

PRT811 (PRMT5 inhibitor) Details
primary central nervous system lymphomas, Cancer, Glioblastoma

Failed

Discontinued